Lisata Therapeutics, Inc.

NasdaqCM LSTA

Lisata Therapeutics, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024

Lisata Therapeutics, Inc. Operating Income Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Lisata Therapeutics, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -21.61%.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

NasdaqCM: LSTA

Lisata Therapeutics, Inc.

CEO	Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.
IPO Date	March 1, 1999
Location	United States
Headquarters	110 Allen Road
Employees	25
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Key trends

Past 5 years